<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The purpose of this study was to determine the potentialof <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> testis (CT) antigens as vaccines for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHLs) </plain></SENT>
<SENT sid="1" pm="."><plain>EXPERIMENTAL DESIGN: Ninety-three specimens of NHLs were analyzed for their composite expression of eight CT genes (MAGE-3, MAGE-4, CT-7, HOM-MEL-40/SSX-2, SSX-1, SSX-4, HOM-<z:chebi fb="34" ids="39035">TES</z:chebi>-14/SCP-1, and HOM-<z:chebi fb="34" ids="39035">TES</z:chebi>-85) </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-nine of these specimens were also analyzed for their NY-ESO-1 expression </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Only 1 of 7 cases of <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> expressed a CT gene (HOM-<z:chebi fb="34" ids="39035">TES</z:chebi>-14/SCP-1), and 10 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were negative for <z:hpo ids='HP_0000001'>all</z:hpo> of the CT genes tested </plain></SENT>
<SENT sid="4" pm="."><plain>In B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, the most frequent expression of CT genes was observed in diffuse large-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (HOM-<z:chebi fb="34" ids="39035">TES</z:chebi>-14/SCP-1: 7 of 28; SSX-1: 5 of 28; CT-7: 2 of 28; and HOM-MEL-40/SSX-2 and HOM-<z:chebi fb="34" ids="39035">TES</z:chebi>-85: 1 of 28 positive cases) </plain></SENT>
<SENT sid="5" pm="."><plain>Only 1 of 8 Burkitt's and 1 of 7 lymphoblastic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> expressed a CT gene (CT7 and HOM-<z:chebi fb="34" ids="39035">TES</z:chebi>-14/SCP-1, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>A majority (9 of 15) of T- NHLs (9 peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 2 lymphoblastic T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and 4 cases of AILD) expressed HOM-<z:chebi fb="34" ids="39035">TES</z:chebi>-14/SCP-1 </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: HOM-<z:chebi fb="34" ids="39035">TES</z:chebi>-14/SCP-1, and to some degree SSX-1 and CT-7 might be candidates for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> vaccine development </plain></SENT>
<SENT sid="8" pm="."><plain>However, the identification of additional <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific antigens with a frequent expression in <z:hpo ids='HP_0002665'>lymphomas</z:hpo> is warranted to allow for the development of widely applicable polyvalent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> vaccines </plain></SENT>
</text></document>